| Primary | The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by Using a Paper Worksheet and a Personalized Electronic LogPad System (E-diary) | The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition. | Validation Analysis Set (VAS) - all OA participants who were non-screen failure at Visit 1 (Screening 1) and returned for Visit 2 (Screening 2); and all enrolled healthy participants. Here, n=number of evaluable participants for each specific category. | Posted | | Mean | Standard Deviation | units on a scale | | Screening 1 (Visit 1: Days -21 to -14) | | | | ID | Title | Description |
|---|
| OG000 | OA Participants | Participants with OA who responded to the WOMAC questionnaire. | | OG001 | Healthy Participants | Healthy participants who responded to the WOMAC questionnaire. |
| | | Title | Denominators | Categories |
|---|
| Pain subscale (paper worksheet) | - ParticipantsOG000356
- ParticipantsOG0010
| |
| |
| Primary | WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 2 by Using E-diary | The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition. | VAS: all OA participants who were non-screen failure at Visit 1 (Screening 1) and returned for Visit 2 (Screening 2). | Posted | | Mean | Standard Deviation | units on a scale | | Screening 2 (Visit 2: Days -14 to -10) | | | | ID | Title | Description |
|---|
| OG000 | OA Participants | Participants with OA who responded to the WOMAC questionnaire. |
| |
| Primary | WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Baseline by Using E-diary | The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition. | FAS: all randomized participants who received at least 1 dose of study medication, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline (Day 1) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
|
| Primary | WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Week 12 by Using E-diary | The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition. | FAS: all randomized participants who received at least 1 dose of study medication, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Mean | Standard Deviation | units on a scale | | Visit 8 (Week 12) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
|
| Primary | Change From Baseline in WOMAC Pain Subscale Scores at Week 12 | WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. | FAS: all randomized participants who received at least 1 dose of study medication using Baseline Observation Carried Forward (BOCF) imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Change From Baseline in WOMAC Subscale and Average Scores at Weeks 2, 4, 8 and 12 | The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. Change from baseline was calculated for each WOMAC subscale (pain, stiffness, physical function) and WOMAC average score. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
|
| Secondary | Change From Baseline in WOMAC Pain Subscale Items at Weeks 2, 4, 8 and 12 | WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. Change from baseline in two of the WOMAC pain subscale items: pain when walking on a flat surface, and pain when going up or down stairs were calculated. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Percentage of Participants With Cumulative Reduction From Baseline in WOMAC Pain Subscale at Week 12 | WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. WOMAC pain subscale response rates at Week 12 were shown for the reductions from Baseline of greater than (>) 0%, 10% to 90% (in steps of 10%). | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Number | | percentage of participants | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Percentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12 | WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure, including the 9 participants (4 placebo, 5 meloxicam) who had missing baseline WOMAC data. | Posted | | Number | | percentage of participants | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Change From Baseline in Patient Global Assessment of Osteoarthritis (PGAO) at Weeks 2, 4, 8 and 12 | PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 scores with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Percentage of Participants With >=2 Points Improvement in PGAO From Baseline at Weeks 2, 4, 8, and 12 | PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 grades with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. The treatment response of an improvement of >=2 points from Baseline in PGAO were summarized. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure, including the 8 participants (3 placebo, 5 meloxicam) who had missing baseline PGAO data. | Posted | | Number | | percentage of participants | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Change From Baseline in Short-Form 36 Health Survey (SF-36) Domain Scores and Component Scores at Week 12 | The SF-36 is a self-administered questionnaire that measures each of the following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure, n=number of evaluable participants for each specific SF-36 domain. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
|
| Secondary | Percentage of Participants With Change From Baseline in EuroQoL-5 Domains (EQ-5D) Level at Week 12 | The EQ-5D is a generic measure of health related quality of life. The EQ-5D has 5 items that assess the level of difficulty (none [score of 1], some/moderate [score of 2], extreme [score of 3]) respondents report for 5 health status domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The change from Baseline (decrease by 2, 1, 0, -1 and -2) at Week 12 in each of the 5 health status domains were summarized. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure, including the 12 participants (5 placebo, 7 meloxicam) who had missing baseline EQ-5D data. | Posted | | Number | | percentage of participants | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |
| Secondary | Change From Baseline in Weekly Average Pain Score in the Index Knee Using 11-point Numeric Rating Scale (NRS) at Weeks 2, 4, 8 and 12 | Daily average knee pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated worse pain. The participants described their pain in the index knee during the past 24 hours by choosing the appropriate number from 0 to 10. | FAS: all randomized participants who received at least 1 dose of study medication using BOCF imputation method, number of participants analyzed=number of participants evaluable for the outcome measure. | Posted | | Least Squares Mean | 95% Confidence Interval | units on a scale | | Baseline, Weeks 2, 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants were randomized to placebo treatment group at Baseline and received matching placebo (2 capsules once daily) for 12 weeks. | | OG001 | Meloxicam 15 mg | Participants were randomized to meloxicam treatment group at Baseline and received meloxicam 7.5 milligram (mg) × 2 once daily for 12 weeks. |
| |